RGEN (Repligen) Beta: 1.0445 (As of Jun. 24, 2026)


RGEN Repligen Corp RGEN
83 GF Score
Price $138.40
GF Value $175.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Beta?

Repligen RGEN +9.50% 83 Beta is 1.0445 as of Jun. 24, 2026. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Repligen's Beta is 1.0445.

Repligen  (NAS:RGEN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Repligen Beta Related Terms

Repligen Beta Historical Data

* Premium members only.

The historical data trend for Repligen's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Beta Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.97 1.19 1.21 1.13

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 1.19 0.95 1.13 1.13

RGEN vs ATR, AVTR, TFX: Beta Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Beta distribution charts can be found below:

* The bar in red indicates where Repligen's Beta falls into.


RGEN
83GF Score
Repligen Corp RGEN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0445 mean?
Repligen (RGEN) has a Beta of 1.0445 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Repligen and its competitors.
Is Repligen's Beta too high?
Repligen's current Beta is 1.0445. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Beta compare to ATR and AVTR?
Repligen's Beta of 1.0445 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Repligen and its competitors. Repligen's current Beta is 1.0445. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.40 — trading 21.3% below its estimated fair value. The current Beta is 1.0445. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Repligen (RGEN), the current Beta is 1.0445 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $138.40 is trading 21.3% below its estimated GF Value™ of $175.89. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Beta: 1.0445
  • GF Value™: $175.89 vs. price of $138.40 (21.3% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score

Get the complete analysis for RGEN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$138.40
Price
$175.89
GF Value